Q BioMed Inc. (QBIO)

OTCMKTS: QBIO · Delayed Price · USD
0.0001
0.00 (0.00%)
Jun 17, 2024, 12:20 PM EDT - Market closed
Market Cap 14.51K
Revenue (ttm) 15,035
Net Income (ttm) 1.48M
Shares Out 145.10M
EPS (ttm) 0.02
PE Ratio 0.01
Forward PE 111.11
Dividend n/a
Ex-Dividend Date n/a
Volume n/a
Open 0.0001
Previous Close 0.0001
Day's Range n/a
52-Week Range 0.0001 - 0.0405
Beta 79.93
Analysts n/a
Price Target n/a
Earnings Date n/a

About QBIO

Q BioMed Inc., a biomedical acceleration and development company, focuses on licensing, acquiring, and providing resources to life sciences and healthcare companies. The company offers Strontium Chloride Sr-89 and Metastron, a radiopharmaceutical therapeutic for the treatment of metastatic bone cancer pain. It is also developing Man-01, that is used for the treatment of primary open angle glaucoma; QBM-001 for rare pediatric non-verbal autism spectrum disorder; and Uttroside-B, a novel chemotherapeutic for liver cancer. Q BioMed Inc. has a part... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2013
Employees 3
Stock Exchange OTCMKTS
Ticker Symbol QBIO
Full Company Profile

Financial Performance

In 2022, Q BioMed's revenue was $284,352, an increase of 45.38% compared to the previous year's $195,597. Losses were -$716,095, -91.81% less than in 2021.

Financial Statements

News

Q BioMed Inc. Provides Update to Shareholders

NEW YORK , June 23, 2023 /PRNewswire/ --  Q BioMed Inc. (OTCQB: QBIO) a biotech acceleration and commercial stage company focused on licensing and acquiring undervalued biomedical assets in the health...

1 year ago - PRNewsWire

Q BioMed Inc. Chemotherapeutic Uttroside B, Receives Patent from United States Patent Office and Notice of Allowance for Europe

NEW YORK, April 14, 2023 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO) a biotech acceleration and commercial stage company focused on licensing and acquiring undervalued biomedical assets in the healthc...

1 year ago - PRNewsWire

Q BioMed Inc. Chemotherapeutic Uttroside B, Receives Notice of Allowance for Patent from United States Patent Office

Uttroside B Has Shown Promising Results in Initial Pre-Clinical Testing NEW YORK , Feb. 10, 2023 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO) a biotech acceleration and commercial stage company focused...

1 year ago - PRNewsWire

Q BIOMED ANNOUNCES ADDITION OF MULTI-MILLION DOLLAR ASSET VALUE WITH EQUITY STAKE IN MANIIN RESEARCH INC.

Company converts future royalty into 15% equity in multi-billion dollar potential product portfolio with additional $20M royalty NEW YORK, Nov. 14, 2022 /PRNewswire/ -- Q BioMed Inc. (QBIO), a commerc...

1 year ago - PRNewsWire

Q BIOMED PROVIDES SHAREHOLDER UPDATE

Focus on Portfolio Monetization and Roll-up Strategy NEW YORK , Oct. 11, 2022 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotechnology acceleration development company, is pleased...

1 year ago - PRNewsWire

Q BIOMED ANNOUNCES ISSUANCE OF PATENT FOR GROUNDBREAKING GDF15 BIOMARKER

Groundbreaking GDF15 biomarker may be the first single examination to accurately predict disease progression in Glaucoma The Certificate of Grant and European Patent No. 3408287  for GDF15 IN GLAUCOMA...

1 year ago - PRNewsWire

Traders News Source Senior Editor Mark Roberts Interviews Denis D Corin, CEO and Chairman Q BioMed Inc.

NEW YORK, NY / ACCESSWIRE / August 25, 2022 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap publicly traded companies recently issue...

1 year ago - Accesswire

Q BioMed Outlines Strategy and Value Proposition in Multi-Billion Dollar Markets

Management's assessment and value of Q BioMed outlined NEW YORK , May 6, 2022 /PRNewswire/ -- Q BioMed, Inc. (OTCQB: QBIO) a commercial-stage biotechnology development company outlines its strategy an...

2 years ago - PRNewsWire

Q BioMed announces publication of research showing augmented efficacy of its drug candidate Uttroside-B against liver cancer

NEW YORK , March 16, 2022 /PRNewswire/ -- Q BioMed, Inc. (OTCQB: QBIO) a commercial-stage biotechnology development company announces a new publication supporting the efficacy and further development ...

2 years ago - PRNewsWire

Q BioMed Announces Initial $500k Order of Strontium89 to Chinese Market

NEW YORK, March 7, 2022 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotech company, announced today that it has received a confirmed $500,000 order for Strontium Chloride USP Inje...

2 years ago - PRNewsWire

Q BioMed Outlines Strategic Direction for 2022

NEW YORK, Feb. 14, 2022 /PRNewswire/ -- Q BioMed Inc.  (OTCQB: QBIO), a biomedical acceleration and development company, focused on licensing, acquiring, and monetizing life science assets, outlines s...

2 years ago - PRNewsWire

Q BioMed Shows Significant Uptrend in Revenues in Year-End Update

NEW YORK, Dec. 16, 2021 /PRNewswire/ -- Q BioMed Inc. (OTCQB:  QBIO), a commercial-stage biotech company, provides this update to shareholders with positive trend in revenues, advancement in pipeline...

2 years ago - PRNewsWire

Q BioMed Inc. Provides Shareholder Update

NEW YORK, Oct. 25, 2021 /PRNewswire/ --  Q BioMed Inc. (OTCQB: QBIO), a biotech acceleration and commercial stage company focused on licensing and acquiring undervalued biomedical assets in the health...

2 years ago - PRNewsWire

Q BioMed Inc. Provides Update on Strontium89 Commercial Roll Out Revenue Up in 4th Quarter with Positive Trend

NEW YORK, Sept. 28, 2021 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO) a biotech acceleration and commercial stage company focused on licensing and acquiring undervalued biomedical assets in the healthc...

2 years ago - PRNewsWire

Q BioMed Inc. Updates on COVID-19 Therapeutic Development and Clinical Trials - MAN-19 therapeutic program heading to clinical trial in early 2022

NEW YORK, Sept. 22, 2021 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO) a commercial stage biotechnology acceleration company, is pleased to provide an update on its partner asset MAN-19 for the treatmen...

2 years ago - PRNewsWire

Q BioMed Inc. Chemotherapeutic Uttroside B, Receives Notice of Allowance for Patent in South Korea and Shows Promising Results in Initial Pre-Clinical Testing

NEW YORK, Aug. 24, 2021 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO) a biotech acceleration and commercial stage company focused on licensing and acquiring undervalued biomedical assets in the healthca...

3 years ago - PRNewsWire

Q BioMed Signs Distribution Agreement with isoSolutions for the Sales of Strontium89 in Canada

NEW YORK, Aug. 10, 2021 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotech company, announced today that it has recently entered into an exclusive distribution agreement with isoS...

3 years ago - PRNewsWire

Q BioMed Signs License Agreement with Clionix for the Distribution and Sales of Strontium89 in Europe and Middle East

NEW YORK, July 12, 2021 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotech company, announced today that it has recently entered into an exclusive license agreement with Clionix, ...

3 years ago - PRNewsWire

Q BioMed Inc. Discusses Progress of COVID-19 Therapeutic and $30 Million Potential Investment with The Stock Day Podcast

Phoenix, Arizona--(Newsfile Corp. - June 23, 2021) - The Stock Day Podcast welcomed Q BioMed Inc. (OTCQB: QBIO) ("the Company"), a biotech acceleration and commercial stage company. CEO of the Company...

3 years ago - Newsfile Corp

Q BioMed Engages Contract Sales Force with Deep VA and Oncology Experience

NEW YORK, May 20, 2021 /PRNewswire/ --  Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotech company, announced today that it has hired WSI PBG, LLC (WSI), a Michigan based firm specializing in cre...

3 years ago - PRNewsWire

Q BioMed Insider to Invest up to $30M in the Company

NEW YORK, May 11, 2021 /PRNewswire/ -- Q BioMed Inc. (OTCQB:  QBIO), announced today that it has signed a securities purchase agreement ("Transaction") with Aedesius Holdings Ltd (AedesiusOne), a pri...

3 years ago - PRNewsWire

Q BioMed Updates Shareholders

NEW YORK, April 27, 2021 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotech company, updates shareholders. In March 2021,it was announced that our technology partner, Mannin Resea...

3 years ago - PRNewsWire

Q BioMed Awarded Federal Supply Contract for Strontium89 with U.S. Department of Defense and Veterans Affairs

NEW YORK, March 2, 2021 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotech company, announced today that it has signed an agreement for Strontium89 (Strontium Chloride Sr-89 Injec...

3 years ago - PRNewsWire

Q BioMed Expands Strontium89 Reach Through Agreement with UroGPO, the Largest Group Purchasing Organization for Independent Urology Clinics in the US

NEW YORK, Feb. 1, 2021 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotech company, announced today that it has been awarded a contract with UroGPO, the largest Group Purchasing Or...

3 years ago - PRNewsWire

Q BioMed's Uttroside-B Receives U.S. FDA Orphan Drug Designation in the Treatment of Liver Cancer

NEW YORK, Jan. 27, 2021 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO), announced today that the U.S. Food and Drug Administration's Office of Orphan Products Development has granted Orphan Drug Designat...

3 years ago - PRNewsWire